ZBIO
Research Snapshot
Static fundamentals, valuation context, and investor signals for Zenas BioPharma, Inc. (ZBIO).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-156.0%
ROIC, -1723.5% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 5.6x current ratio
Superinvestors
1
Top: Meridian Contrarian Fund (0.3%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
Watchouts
- Free cash flow margin is negative at -1723.5%.
- Valuation multiples are limited or unavailable.
Annual data: 3 periods
Quarterly data: 12 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ZBIO.
Grade F
1
/ 100
Financial Charts
No financial data available for ZBIO (annual).
1 superinvestors own ZBIO
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Meridian Contrarian Fund Meridian Contrarian Fund | 183,812 | $1M | 0.26% | ▼ -24.6% |